They both block TNF-alpha, that inflammation signal, but in different ways only. One is a lab-made copy of our immune system’s antibody, like infliximab. The other is a clever stitch-job, fusing our TNF receptor to a stable antibody part, like etanercept itself.
From my desk, I see the fusion protein claims are often less disputed by the insurers—maybe because the dosing is simpler and it looks more "human" to their formulas.
But my own view? After fighting for my daughter’s pharmacy books, I know the science is solid for both. The real difference is which one the insurance wallahs decide to approve without three rounds of appeals.
#work#career
Jump in to reply — no account needed.